scholarly journals Anticoagulation Therapy for Pregnant Women With Mechanical Prosthetic Heart Valves

2017 ◽  
Vol 69 (22) ◽  
pp. 2692-2695 ◽  
Author(s):  
Uri Elkayam
Keyword(s):  
Pregnant Women ◽  
Heart Valves ◽  
Anticoagulation Therapy ◽  
Prosthetic Heart Valves

scholarly journals THE ROLE OF ANTICOAGULATION THERAPY IN PATIENTS WITH PROSTHETIC HEART VALVES

The Clinician ◽  
2016 ◽  
Vol 10 (2) ◽  
pp. 10-17 ◽  
Author(s):  
N. A. Shostak ◽  
A. A. Klimenko ◽  
D. Y. Andriyashkina ◽  
A. A. Kondrashov ◽  
A. V. Novikova
Keyword(s):  
Heart Valves ◽  
Anticoagulation Therapy ◽  
Prosthetic Heart Valves

scholarly journals Prophylaxis of thrombotic complications in a pregnant patients with prosthetic heart valves

2012 ◽  
Vol 61 (5) ◽  
pp. 10-24
Author(s):  
Aleksandr Davidovich Makatsariya ◽  
Viktoriya Omarovna Bitsadze ◽  
Dzhamilya Khizriyevna Khizroyeva ◽  
Vyacheslav Borisovich Nemirovskiy ◽  
Svetlana Vladimirovna Akinshina
Keyword(s):  
Heart Valve ◽  
Heart Valves ◽  
Anticoagulation Therapy ◽  
Mechanical Heart Valve ◽  
Prosthetic Heart Valves ◽  
Dose Selection ◽  
Heart Valve Prostheses ◽  
Adequate Dose ◽  
Thrombotic Complications ◽  
Valve Prostheses

In patients with prosthetic heart valves pregnancy and labor are associated with high risk. There are no established anticoagulation guidelines in pregnant women with mechanical heart valve prostheses. More often physiological hypercoagulable state during pregnancy can reveal acquired and/or inherited hemostasis abnormalities which were asymptotic before pregnancy. The presence in the history of patients the foetal loss syndrome, severe obstetric complications (severe preeclampsia, abruptio placenta, antenatal fetal death, feto-placental insufficiency), thrombosis events is an indication for the screening for genetic thrombophilia and antiphospholipid syndrome. The diagnosis of thrombophilia in patients with mechanical heart valve prostheses can explain the inefficiency of anticoagulation therapy, warfarin resistance, «floating» hemostasis markers and difficulties in adequate dose selection

In-Vitro Thrombogenicity Assessment of Mechanical Circulatory Support Devices and Prosthetic Heart Valves

2010 ◽  
Author(s):  
Thomas E. Claiborne ◽  
Gaurav Girdhar ◽  
Jawaad Sheriff ◽  
Jolyon Jesty ◽  
Marvin J. Slepian ◽  
...  
Keyword(s):  
Platelet Activation ◽  
Mechanical Circulatory Support ◽  
Heart Valves ◽  
Anticoagulation Therapy ◽  
Ventricular Assist Devices ◽  
Patient Specific ◽  
Circulatory Support ◽  
Prosthetic Heart Valves ◽  
Bridge To Transplant ◽  
Uncontrolled Bleeding

Mechanical circulatory support (MCS) devices developed for end-stage heart failure or as a bridge-to-transplant include total artificial hearts (TAH) and ventricular assist devices (VAD) and utilize prosthetic heart valves (PHV) or rotary impellers to control blood recirculation [1]. These devices are currently not optimized to reduce the incidence of pathological flow patterns that cause elevated stresses leading to platelet activation and thrombosis. Although the latter is partially mitigated by lifelong anticoagulation therapy, it dramatically increases the risk of uncontrolled bleeding. For instance thromboembolic stroke-related complications (∼2%) were relatively less with the TAH-t compared to uncontrolled bleeding due to anticoagulation use (∼20%) [2]. Platelet activation should therefore be quantified and optimized based on patient-specific cardiac outputs in device prototypes before clinical use.

Sign in / Sign up

Export Citation Format

Share Document